Menu
Close
Stories & News
Resources
Stay Informed
x
Stay Informed
July 10, 2025
At Pfizer, we are committed to translating advanced science and technologies into the therapies that matter most – delivering reliable medicines and vaccines to patients and providers worldwide.
These efforts are underpinned by our pursuit of responsible business growth – the idea that companies are more likely to succeed if they demonstrate value for all their stakeholders, from employees, patients, and communities to suppliers, customers and shareholders. This commitment is embedded into Pfizer’s strategic decision-making and is a key contributor to our performance and objective to create long-term value.
Our 2024 Impact Report details the progress we have made over the past year to deliver responsible business growth. From expanding affordable access to our breakthrough medicines to accelerating product innovation through reduced cycle times and increased success rates, our initiatives reflect our unwavering dedication to making a positive impact on the world.
Please refer to Pfizer’s 2024 Impact Report for additional information regarding the metrics included herein, including the footnotes within the Performance section.
The global health landscape is continually evolving, and we are keeping pace, driving innovation to help address an array of challenges as we strive to change one billion lives annually by 2027. But delivering breakthroughs is only part of the equation. We are also focused on getting those medicines and vaccines to patients who need them, regardless of where they live, through enhanced product and care delivery systems.
In 2024, we continued to advance our work to discover, develop, and bring to market breakthroughs that change patients’ lives, including:
Forward-Looking Statements: Forward-looking statements included herein and in the linked content, including those related to our anticipated operating and financial performance, our productivity improvement initiatives, our research and development strategy and productivity, our product and pipeline advancements and candidates, and our capital allocation strategy and dividend, speak only as of the original date they were made and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website at sec.gov. Please also refer to our 2024 Impact Report, which is available on our website at pfizer.com.
1The FIH to approval NME success rate metric is a composite metric. It is a cumulative success rate derived using individual phase success rates from FIH (start of Phase 1) to approval (first regulatory approval) at an NME level. Combinations of approved NMEs, biosimilars and generics are excluded from all success rate calculations. Cumulative NME success rate is calculated using three-year rolling cohorts for Phase 1 and five-year rolling cohorts for Phase 2, Phase 3 and registration.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.